Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio,[2][1][3] employing approximately 5,400 people.

He began his career as a reviewer with the FDA, specializing in the development of lipid lowering therapies to treat high cholesterol.

[5] Another Medpace physician, David Orloff was regarded as an industry opinion leader in the study of metabolic diseases – most specifically diabetes and obesity.

[8] The project encompassed revitalizing an urban brownfield site formerly occupied by NuTone, and creating a state of the art LEED (Leadership in Energy and Environmental Design) certified campus.

[9] In 2022, Medpace announced a $150 million capital investment to expand its headquarters in Cincinnati, Ohio, adding an estimated expansion of 1,500 new jobs.